with low dose LV. Based on these reports, a first-line Phase II study was performed in 101 patients with advanced colorectal carcinoma who were given a bimonthly
Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma
✍ Scribed by Christophe Tournigand; Christophe Louvet; Aimery de Gramont; Elisabeth Lucchi; Jean-François Seitz; Frédéric Mal; Eric Raymond; Jean Cady; Elisabeth Carola; Marcel Krulik; for the Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD)
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 88 KB
- Volume
- 79
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
disease progression. IFN was administered subcutaneously three times weekly at for the Groupe d'Etude et de a dose of 3 MU (body surface area [BSA] õ 1.75 m 2 ) or 4.5 MU (BSA ¢ 1.75 m 2 ). Recherche sur les Cancers de RESULTS. World Health Organization toxicity Grade 3-4 occurred in 21 patients l'Ovaire et Digestifs (GERCOD)
(42%): diarrhea in 6%, mucositis in 12%, neutropenia in 30%, and alopecia in 8%.
The overall response rate was 44%; 1 patient had a complete response (2%), 21 had
📜 SIMILAR VOLUMES
## BACKGROUND. Reports of in vitro experiments in colorectal carcinoma cells suggest that prolonged cellular exposure to 5-fluorouracil (5-FU) combined with relatively low concentrations of leucovorin (LV) provides optimal enhancement of 5-FU efficacy. In this study, a simplified regimen of weekly
## BACKGROUND. The biochemical modulation of 5-fluorouracil (5-FU) by leucovorin (Lv) has demonstrated significantly increased response rates in comparison with the use of 5-FU alone in patients with advanced colorectal carcinoma. However, the higher response rate of LV/5-FU may occur at the expen